FMR LLC has updated its beneficial ownership in Royalty Pharma plc, now holding 4.3% of the company’s Class A common stock. This change, reported in a Schedule 13G/A filing, signifies a notable investment in the pharmaceutical preparations sector.

Royalty Pharma plc, listed on Nasdaq under the ticker RPRX, is a prominent player in the pharmaceutical preparations industry, focusing on acquiring and managing revenue-generating pharmaceutical royalties. The company has been active in the market, as evidenced by its recent filings, including a 10-Q and an 8-K on November 4, 2026.

The recent filing details that FMR LLC beneficially owns approximately 19,288,880 shares of Royalty Pharma, which translates to a significant stake in the company. FMR LLC's ownership includes sole voting power over about 14,091,863 shares. The filing states, "This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies."

This increased ownership could potentially influence Royalty Pharma's strategic decisions and market positioning. The filing also highlights Abigail P. Johnson, who serves as a Director, Chairman, and CEO of FMR LLC, indicating her significant role in the investment decisions made by the firm.

FMR LLC's investment strategy appears to align with its broader objectives in the pharmaceutical sector, which may affect competing firms in the industry. The filing does not specify what actions FMR LLC plans to take next regarding its stake in Royalty Pharma, leaving the market to speculate on future developments.

Overall, this update from Royalty Pharma plc showcases the ongoing interest from major investment firms in the pharmaceutical preparations industry, emphasizing the sector's potential for growth and investment opportunities.